StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > US OTC Listing upgrade

<< Previous

Bullboard Posts

Next >>

Comment by StockscoutXon Jun 15, 2021 9:32am

118 Views

Post# 33387443

RE:US OTC Listing upgrade

Does OTC listing upgrade add to the bottom line or improves the fundamentals? No. Only "smoke and mirrors" for the gullible retail investor but savy investors will not take the bait. There will be no excitement for this stock for a long time to come. SP will stagnate for months to come.

LithLover wrote: Anyone else notice we just recently moved from the Greys to Pinks on the US OTC.

Next, Tripp mentioned eyeing the OTCQB in a recent interview.

Shift Communications, OTCQB uplisting, closing the Care Oncology deal, annual meeting June 30.

Lots going on in the background here.